Bristol-myers Squibb Compnay

David Hagerty

Robert Peach

Jean-Claude Becker

Robert Cohen

Suzette Belder-Carr

Suzette Carr

Peter S Linsley

Jurgen Bajorath

Joseph Naemura

James Rusnak

Robert J Peach

The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule

The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Methods for treating scleroderma by administering a soluble CTLA4 molecule

The present invention relates to compositions and methods for treating autoimmune diseases, such as Sjogren's syndrome, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule

The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule

The present invention relates to compositions and methods for treating autoimmune diseases, such as diabetes, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule

The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).

Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID

The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Method for treating a rheumatic disease using a soluble TLA4 molecule

The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.

Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules

The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.

Growing community of inventors

Cardiff by the Sea, CA, United States of America

David Hagerty